• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Study of the mechanism of cancer-risk increase due to diabetes and suggestion of the molecular-targeting cancer prevention for the cancer

Research Project

Project/Area Number 16H05260
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Research Field Hygiene and public health
Research InstitutionKyoto Prefectural University of Medicine

Principal Investigator

TOMOSUGI (HORINAKA) Mano  京都府立医科大学, 医学(系)研究科(研究院), 講師 (80512037)

Project Period (FY) 2016-04-01 – 2019-03-31
Project Status Completed (Fiscal Year 2018)
Budget Amount *help
¥16,510,000 (Direct Cost: ¥12,700,000、Indirect Cost: ¥3,810,000)
Fiscal Year 2018: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2017: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2016: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Keywordsがん予防 / 糖尿病 / TRAIL / 癌予防
Outline of Final Research Achievements

TRAIL is a cytokine which can induce apoptosis against cancer cells, and contribute to cancer prevention. We have focused on TRAIL and examined whether the decline of immunity due to diabetes resulted in the down-regulation of TRAIL expression causing subsequent carcinogenesis and the up-regulation of leptin expression.
We compared the expression of TRAIL mRNA of the organ samples from a type 2 diabetes model of the mouse with those from the control mouse. As the results, TRAIL expressions of cDNA samples derived from lung of the diabetes model animals were lower than those from control mouse. Next, we showed the suppressive effect of leptin against the IFN-activated PBMCs to produce TRAIL. Furthermore, we focused on PED which were reported to be overexpressed in type 2 diabetes mellitus and mediate TRAIL resistance in human non-small cell lung cancer. Therefore, we tried the screening of the down-regulator of PED expression.

Academic Significance and Societal Importance of the Research Achievements

本邦では複数の疫学研究の結果から「日本人糖尿病患者の癌罹患リスク増大」が報告され、重大な社会的問題として取り上げられているが、その分子機序については現在も十分に明らかとされていない。本研究課題の成果は、癌予防に寄与するサイトカインであるTRAILの発現低下が、その一機序の説明になりうるかもしれないことを示している。研究代表者らが取り組んでいる、TRAIL経路の活性化による癌予防法の提案・応用に向けて、今回の研究成果が生かせられると考えている。

Report

(4 results)
  • 2018 Annual Research Report   Final Research Report ( PDF )
  • 2017 Annual Research Report
  • 2016 Annual Research Report
  • Research Products

    (7 results)

All 2018

All Journal Article (3 results) (of which Peer Reviewed: 3 results) Presentation (4 results) (of which Invited: 1 results)

  • [Journal Article] Sulindac sulfone inhibits the mTORC1 pathway in colon cancer cells by directly targeting voltage-dependent anion channel 1 and 22018

    • Author(s)
      Aono Yuichi、Horinaka Mano、Iizumi Yosuke、Watanabe Motoki、Taniguchi Tomoyuki、Yasuda Shusuke、Sakai Toshiyuki
    • Journal Title

      Biochemical and Biophysical Research Communications

      Volume: 505 Issue: 4 Pages: 1203-1210

    • DOI

      10.1016/j.bbrc.2018.10.050

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed
  • [Journal Article] The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.2018

    • Author(s)
      Ono H, Sowa Y, Horinaka M, Iizumi Y, Watanabe M, Morita M, Nishimoto E, Taguchi T, Sakai T.
    • Journal Title

      Breast Cancer Research and Treatment

      Volume: 171 Issue: 1 Pages: 43-52

    • DOI

      10.1007/s10549-018-4815-x

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed
  • [Journal Article] FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically inhibit cell growth and induce apoptosis in bladder cancer cells.2018

    • Author(s)
      Takamura T, Horinaka M, Yasuda S, Toriyama S, Aono Y, Sowa Y, Miki T, Ukimura O, Sakai T.
    • Journal Title

      Oncology Reports

      Volume: 39 Pages: 627-632

    • DOI

      10.3892/or.2017.6127

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed
  • [Presentation] FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically induce apoptosis in bladder cancer cells.2018

    • Author(s)
      堀中真野, 曽和義広, 三木恒治, 浮村理, 酒井敏行.
    • Organizer
      第77回日本癌学会学術総会
    • Related Report
      2018 Annual Research Report
  • [Presentation] The novel combination treatment of a HDAC inhibitor OBP-801 with eribulin for triple-negative breast cancer cells.2018

    • Author(s)
      小野寿子, 曽和義広, 堀中真野, 飯泉陽介, 渡邉元樹, 田口哲也, 酒井敏行.
    • Organizer
      第77回日本癌学会学術総会
    • Related Report
      2018 Annual Research Report
  • [Presentation] 食べて防ごう! がん化学予防への挑戦!2018

    • Author(s)
      堀中真野.
    • Organizer
      おかやまバイオアクティブ研究会第53回シンポジウム
    • Related Report
      2018 Annual Research Report
    • Invited
  • [Presentation] FGFR阻害剤BGJ398とHDAC阻害剤OBP-801との併用による、膀胱癌に対する分子標的治療戦略.2018

    • Author(s)
      堀中真野, 曽和義広, 酒井敏行.
    • Organizer
      第22回日本がん分子標的治療学会学術集会.
    • Related Report
      2018 Annual Research Report

URL: 

Published: 2016-04-21   Modified: 2020-03-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi